ESR1 and breast cancer: Stromal tumor-infiltrating lymphocytes (sTIL) are important indicators of the immune response and prognosis in breast cancer; however, their predictive and prognostic roles in ER + HER2- breast cancer remain unclear [17, 36, 37].